百诚医药：创新药BIOS-0623-Z4片获得临床试验批准

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) has received clinical trial approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug BIOS-0623-Z4 tablets, which are aimed at treating cancer pain in adults and are the first of their kind in this indication [1] Group 1 - The drug BIOS-0623-Z4 tablets utilize a non-opioid target mechanism for adult cancer pain treatment [1] - There are currently no other drugs on the market with the same target mechanism and indication as BIOS-0623-Z4 tablets [1] - BIOS-0623-Z4 tablets are classified as a Class 1 chemical drug and are categorized as an innovative drug that has not been launched domestically or internationally [1]